국가: 캐나다
언어: 영어
출처: Health Canada
TERBINAFINE (TERBINAFINE HYDROCHLORIDE)
SIVEM PHARMACEUTICALS ULC
D01BA02
TERBINAFINE
250MG
TABLET
TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250MG
ORAL
30/100
Prescription
ALLYLAMINES
Active ingredient group (AIG) number: 0132855002; AHFS:
APPROVED
2016-06-01
_ _ _Product Monograph _TERBINAFINE_ _ _Page 1 of 44_ PRODUCT MONOGRAPH PR TERBINAFINE (Terbinafine Hydrochloride Tablets) 250 mg Terbinafine as Terbinafine hydrochloride Antifungal Agent Sivem Pharmaceuticals ULC 4705 Dobrin Street Saint-Laurent, Quebec, Canada H4R 2P7 www.sivem.ca Date of Revision: December 10, 2019 SUBMISSION CONTROL NO.: 233709 _ _ _Product Monograph _TERBINAFINE_ _ _Page 2 of 44_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 10 DOSAGE AND ADMINISTRATION ............................................................................. 13 DOSING CONSIDERATIONS ........................................................................................ 14 OVERDOSAGE ............................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 14 STORAGE AND STABILITY ......................................................................................... 15 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 16 PART II: SCIENTIFIC INFORMATION ............................................................................... 17 PHARMACEUTICAL INFORMATION ........................................................... 전체 문서 읽기